Home / Health / Personalized Drugs Manufactured On-Site to Accelerate Life-Saving Therapies
Personalized Drugs Manufactured On-Site to Accelerate Life-Saving Therapies
2 Aug
Summary
- UK first country to relax strict manufacturing rules for time-sensitive treatments
- Patients can now receive personalized cancer and rare genetic disorder drugs within days
- Mobile units deployed to finish drug manufacturing at patients' bedsides
As of August 2, 2025, the UK has become the first country in the world to relax the strict manufacturing rules that previously caused delays in time-sensitive medical treatments. This new regulation, introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), will enable cancer patients and those with rare genetic disorders to receive personalized drugs made at their bedsides, rather than having to wait for the treatments to be produced hundreds of miles away.
Many of these advanced therapies involve modifying a patient's own cells or genetic code, which requires a bespoke approach. Previously, the samples had to be taken and edited in specialized facilities, often leading to critical delays as patients became too unwell to receive the treatment or the medicine itself did not survive the journey. Now, the final steps of the manufacturing process can be completed closer to the patient, reducing the time it takes to produce a life-saving treatment from months to just days.
In addition to the on-site manufacturing capabilities at hospitals, the MHRA will also deploy mobile units to finish the drug production for patients who are too sick to leave their homes or need to limit hospital visits due to weakened immune systems. This innovative approach aims to bring cutting-edge care directly to patients when they need it most, allowing them to receive personalized therapies and return home more quickly.
